Clinically, the ATTAIN Phase 3 program showed that orforglipron at its highest dose delivered a mean weight loss of 12.4% over 72 weeks, slightly less than the WEGOVY pills 13.6% at 64 weeks, but with a broader, more diverse patient population of over 3,000 participants
Wegovy may temporarily worsen reflux symptoms during initial treatment due to delayed gastric emptying, but successful weight loss often improves hiatal hernia symptoms long-term by reducing intra-abdominal pressure
However, the available clinical evidence was limited by substantial heterogeneity, low event rates, and imprecise estimates 56
Secondary outcomes are reported in Table 2
We invite you to take our free assessment quiz to see if you qualify for our prescription weight loss medications